Osteoarthritis and Cartilage Vol. 15, Supplement C C89 DNA methylation in the IL-1β promoter in 3/5 patients. Further work concentrated on this gene. Bisulfite modification suggested that the CpG sites at -290bp and -247bp were important for the epigenetic regulation of IL-1β, and the site at -290bp was selected for quantification of DNA methylation. We then determined which experimental conditions resulted in the greatest loss of DNA methylation and whether this paralleled the increase in mRNA expression. Culture with the de-methylating factor 5-aza-dC halved DNA methylation, which resulted in 4-8 fold increases in IL-1β expression compared with cultured controls. This demonstrated that DNA de-methylation per se increased gene expression. However, this was not the only factor involved, since far greater effects were seen with the inflammatory cytokines: IL-1β reduced methylation to ∼15%, cresulting in 50-100 fold increases in gene expression. The greatest effect was seen with TNF-α/OSM, which abolished DNA methylation almost completely and caused IL-1β expression to increase 500-1000 fold. The cytokine-induced expression was translated into protein. Unlike IL-1β, TNF-α expression was not susceptible to auto-induction or epigenetic control. Conclusions: A system has been developed in which loss of DNA methylation in combination with 100-1000 fold increases in gene expression can be induced experimentally -a crucial prerequisite for mechanistic studies. Moreover, we demonstrated for the first time that inflammatory cytokines can cause loss of DNA methylation in addition to all other known effects, and that IL-1β (but not TNF-α) induces its own expression. Purpose: Our previous work revealed differential roles for the NF-κB activating kinases in controlling the progression towards terminal differentiation of primary osteoarthritic chondrocytes. Here we elaborate some of the multiple steps whereby IKKα controls the terminal chondrogenic differentiation program. Methods: Primary chondrocytes were derived from 15 Osteoarthritis (OA) patients undergoing joint arthroplasty. IKKα or IKKβ shRNAs were stably expressed by pSuper retroviral transduction of IKKα or IKKβ specific shOligos followed by selection of puromycin resistant cells and KD efficiencies were verified by immunoblotting. High density monolayer and micromass cultures under mineralizing conditions were selected to investigate the mechanisms whereby the IKKs control chondrocyte terminal differentiation. Runx2 was evaluated by both REAL TIME PCR in 1 week old micromasses and by immunohistochemistry in 3 week old micromasses and Sox9 expression in high density monolayer cultures by immunoblotting. The effects of IKKα KD on type 2 collagen accumulation at the transcriptional or post-translational levels were investigated in micromasses. ECM remodelling was directly evaluated by staining for neoepitopes (Col2 3/4 C and DIPEN and NITEGE). Moreover, IKKα expression was rescued in IKKα KD chondrocytes with either a wild type or kinase-dead IKKα(K44M) mutant to explore the connection between IKKα's effects on chondrogenesis and the NF-κB pathway. Results: IKK KDs were at least 80% and generally greater than 90%. Both IKK KD were found associated with increased Col2 mRNA expression and also resulted in defective ECM remodelling as shown by IHC detection of neoepitopes. Silencing IKKβ markedly increased sGAG accumulation, in conjunction with increased Sox9 expression. However, IKKα ablation markedly enhanced collagen 2 deposition independently of Sox9 but instead in association with a strong remodelling block in conjunction with Runx2 suppression. In addition ablation of either IKKα or IKKβ also inhibited Collagen X deposition thus providing additional evidence, along with blocks in calcium deposition, that each IKK (albeit via different mechanisms) is of central importance for progression towards terminal differentiation.
Purpose: Our previous work revealed differential roles for the NF-κB activating kinases in controlling the progression towards terminal differentiation of primary osteoarthritic chondrocytes. Here we elaborate some of the multiple steps whereby IKKα controls the terminal chondrogenic differentiation program. Methods: Primary chondrocytes were derived from 15 Osteoarthritis (OA) patients undergoing joint arthroplasty. IKKα or IKKβ shRNAs were stably expressed by pSuper retroviral transduction of IKKα or IKKβ specific shOligos followed by selection of puromycin resistant cells and KD efficiencies were verified by immunoblotting. High density monolayer and micromass cultures under mineralizing conditions were selected to investigate the mechanisms whereby the IKKs control chondrocyte terminal differentiation. Runx2 was evaluated by both REAL TIME PCR in 1 week old micromasses and by immunohistochemistry in 3 week old micromasses and Sox9 expression in high density monolayer cultures by immunoblotting. The effects of IKKα KD on type 2 collagen accumulation at the transcriptional or post-translational levels were investigated in micromasses. ECM remodelling was directly evaluated by staining for neoepitopes (Col2 3/4 C and DIPEN and NITEGE). Moreover, IKKα expression was rescued in IKKα KD chondrocytes with either a wild type or kinase-dead IKKα(K44M) mutant to explore the connection between IKKα's effects on chondrogenesis and the NF-κB pathway. Results: IKK KDs were at least 80% and generally greater than 90%. Both IKK KD were found associated with increased Col2 mRNA expression and also resulted in defective ECM remodelling as shown by IHC detection of neoepitopes. Silencing IKKβ markedly increased sGAG accumulation, in conjunction with increased Sox9 expression. However, IKKα ablation markedly enhanced collagen 2 deposition independently of Sox9 but instead in association with a strong remodelling block in conjunction with Runx2 suppression. In addition ablation of either IKKα or IKKβ also inhibited Collagen X deposition thus providing additional evidence, along with blocks in calcium deposition, that each IKK (albeit via different mechanisms) is of central importance for progression towards terminal differentiation.
Conclusions:
We have uncovered an unexpected, pivotal role for IKKα in the terminal chondrogenesis of primary osteoarthritic human chondrocytes. IKKα controls the transition to the hypertrophic phase at multiple levels, while IKKβ appears to mimick the effects of canonical NF-κB activation. Preliminary indications of an IKKα rescue experiment suggest that its more profound effects could be independent of the NF-κB pathway. In conjunction with the healthier status of IKKα KD chondrocytes, with respect to their extensive ECM and high viability, our results support the view that IKKα could be a novel therapeutic target for Osteoarthritis with its ablation causing a profound blockage towards terminal differentiation. Acknowledgements: Supported by the CARISBO Foundation (Contract Grant number: 2005-1059); grants from Bologna University; Ricerca Corrente Istituti Ortopedici Rizzoli. KBM greatfully acknowledges the support of the CRBA, Bologna University.
APOLIPOPROTEIN A-1 IS A NOVEL INDUCER OF AGGRECAN BREAKDOWN IN CULTURED ARTICULAR CARTILAGE
A. Didangelos, Y. Sawaji, R. Wait, J. Saklatvala Imperial College, London, United Kingdom Purpose: While investigating the effects of sharp injury upon inflammatory signalling pathways in articular cartilage, we found that synovial fluid strongly activated MAP kinases in cartilage explants adapted to culture. We set out to identify the activator and investigate its effects on chondrocyte function. Methods: Cartilage from porcine metacarpophalangeal joints was cultured in serum-free medium for 24h before treatment with porcine synovial fluid. Tissue extracts were analysed for MAPK (ERK, p38 and JNK) and ATF-2 (a preferred JNK substrate) activation by phospho-Western blotting. Culture medium samples were analysed for the presence of aggrecanase-generated aggrecan fragments by using antibodies against the aggrecan ARGS neoepitope. Porcine synovial fluid was subjected to sequential chromatography (Resource Q, Resource S and Blue Sepharose) and the MAPK activator was identified by massspectrometry. Results: The porcine synovial fluid activator was identified as apolipoprotein A-1 (APOA-1) the major component of high density lipoprotein (HDL) in tissue fluids. Porcine APOA-1 purified from synovial fluid and commercially available human APOA-1 activated MAPKs and also induced aggrecan breakdown in cultured cartilage. APOA-1 induced mRNA of ADAMTS-4 and -5 and MMP-13. APOA-1 differed from typical inflammatory mediators that cause cartilage catabolism (IL-1, TNF, LPS), in that it did not induce cyclooxygenase-2 (COX-2), a typical inflammatory response gene. Conclusions: APOA-1 in synovial fluid causes MAPK activation and induces aggrecanases in cartilage. It appears to cause a matrix-resorbing response without inducing inflammatory response genes. APOA-1 (apparent Mr ∼120kD) may normally be excluded from the cartilage matrix but is perhaps able to access the cut surface of explants. Alternatively, chondrocytes in cultured tissue may acquire sensitivity to this ubiquitous component of tissue fluid. These possibilities are under investigation.
DECOY RECEPTOR 3 INDUCES CELL PROLIFERATION THROUGH MAPK SIGNALS IN OSTEOARTHRITIS CHONDROCYTES
H. Shinya, N. Takayuki, M. Yasushi, H. Shingo, K. Masahiro Kobe University, Kobe, Japan Purpose: Decoy receptor 3 (DcR3), a newly identified member of the TNF receptor (TNFR) superfamily, is a soluble receptor binding to the TNF family including Fas-ligand (Fas-L), LIGHT, and TL1A. DcR3 is mostly expressed in tumor cells and competitively inhibits TNF binding to TNFR. In this study, we investigated DcR3 expression and analyzed DcR3 function in osteoarthritis (OA) cartilage. Methods: Expressions of DcR3 in chondrocytes were measured by RT-PCR and westernblotting. OA chondrocytes were incubated with DcR3-Fc chimera protein (DcR3-Fc) before induction of apoptosis. Apoptosis induced by Fas in OA chondrocytes were detected with TUNEL staining and westernblotting of caspase 8 and poly (ADP-ribose) polymerase (PARP). Proliferation of chondrocytes were analysed by WST assay. After incubation with DcR3-Fc, PD098059 or SB203580. Activation of extracellularsignal regulated kinase (ERK), P38 mitogen-activated protein kinase (P38MAPK) and c-jun N-terminal kinase (JNK) in chondrocytes were measured by westernblotting. Results: DcR3 mRNA and protein were expressed in OA chondrocytes. RT-PCR and real-time PCR revealed that DcR3 mRNA was expressed in all the individual samples of OA and normal chondrocytes (Fig. 1a) . Western blotting confirmed that DcR3 protein was expressed in OA and normal chondrocytes (Fig. 1b) . DcR3 protein inhibited Fas-induced apoptosis in chondrocytes. TUNEL positive apoptotic cells induced by Fas-L in chondrocytes were significantly decreased in a dose dependent manner when chondrocytes were pre-incubated with DcR3-Fc protein (Fig.  2a) . Cleavage of caspases were also significantly decreased (Fig. 2b) . DcR3 stimulates chondrocytes proliferation. Proliferation assay revealed that the growth rates of chondrocytes were not signif- icantly increased by the treatments with 5000 ng/ml of IgG1 in control medium. However, the growth rates of chondrocytes were significantly increased by the treatments with least 1000 ng/ml of DcR3-Fc in control medium (Fig. 2c) , DcR3 stimulates the ERK signaling pathway. Western blotting revealed that ERK signaling was activated by the treatment with 5000 ng/ml of DcR3-Fc for 10 min (Fig. 3) However, Neither P38 MAPK nor JNK signaling was not activated by the treatment with 5000 ng/ml of DcR3-Fc for up to 30 min (Fig. 3) . Suppression of ERK activity decreased chondrocytes proliferation introduced by DcR3. Proliferation assay revealed that chondrocytes proliferation were significantly increased by the treatment with 5000 ng/ml of DcR3-Fc. chondrocytes proliferation were inhibited by the treatment with 5000 ng/ml of DcR3-Fc and PD098059 (Fig. 4a) . Chondrocytes proliferation were increased by the treatment with 50µM of SB203580, and proliferation were more increased by the treatment with SB203580 and DcR3-Fc (Fig. 4a) . Western blotting confirmed that the activation of ERK signaling was inhibited by the treatment with 5000 ng/ml of DcR3-Fc and PD 98059 (Fig. 4b) . Conclusions: Our results strongly suggest that DcR3 actually protects OA chondrocytes from death via Fas-induced apoptosis
